[Development and biochemical characterization of EGFR/c-Met dual inhibitors]

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is a key target in non-small cell lung cancer (NSCLC).
• Resistance to EGFR inhibitors (gefitinib, erlotinib, lapatinib) develops in 18-20% of NSCLC cases due to c-Met amplification or secondary EGFR mutations.
• There is a clinical need for novel therapeutics that can overcome this resistance.

Purpose of the Study:

• To develop novel quinoline-based compounds targeting both EGFR and c-Met kinases.
• To evaluate the efficacy of these dual inhibitors in vitro and in vivo.
• To investigate the binding mechanisms of effective compounds through computational simulations.

Main Methods:

• Enzymatic assays to determine kinase inhibition.
• Western blot analysis to assess in vivo autophosphorylation inhibition.
• In silico and docking simulations to examine compound binding.

Main Results:

• Developed quinoline-based inhibitors demonstrating submicromolar activity against both EGFR and c-Met kinases.
• Confirmed in vivo inhibition of EGFR and c-Met autophosphorylation by the developed compounds.
• Computational simulations provided insights into the binding interactions of effective inhibitors.

Conclusions:

• The novel quinoline-based compounds are potent dual inhibitors of EGFR and c-Met.
• These findings present a promising new therapeutic strategy for overcoming resistance in NSCLC.
• Further development of these compounds could lead to improved treatments for NSCLC patients.